Dr. Pietras on Palliative Care for Patients With Ovarian Cancer

Video

In Partnership With:

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.

Though there are no large randomized trials, there are smaller studies that suggest that ketamine may be beneficial when used appropriately for patients with very difficult to control pain symptoms who are already on very high doses of opioids and non-opioid adjuvant medicines like gabapentin (Neurontin) for pain. Ketamine can significantly improve pain scores in up to half of patients, says Pietras, though physicians still need to do larger studies and prospective trials to confirm if these data are correct or not.

Pietras says that ketamine should only be used in a select group of patients who have uncontrollable pain—despite highly escalated opioids and other medications—and in patients who do not have traits that would make them more likely to have side effects. This includes patients who might feel confused and those who have anxiety, as those are the most common side effects with ketamine. Pietras notes that it is also important not to increase the dose too high too quickly because hallucinations are often seen at high doses.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD